Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793244 | 0.86 | CD44 (0.42) | PNMTCD44MAOB | |
| SCHEMBL28948226 | 0.79 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2CPRCP | |
| SCHEMBL3079019 | 0.74 | BCL2L1 (0.39) | — | |
| SCHEMBL16650011 | 0.74 | PARP1 (0.37) | MAOB | |
| SCHEMBL17196035 | 0.74 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL2261217 | 0.71 | DRD2 (0.42) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL23714763 | 0.70 | BRD4 (0.33) | — | |
| SCHEMBL8312582 | 0.70 | DRD2 (0.46) | ADRA2AADRA2BADRA2CMAOB | |
| SCHEMBL22306887 | 0.69 | BRD4 (0.35) | PNMT | |
| SCHEMBL25604386 | 0.69 | BRD4 (0.37) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC (US) | 2022-07-07 | — | — | US | disclosed |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | NUVATION BIO INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | NUVATION BIO INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3873474-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Nuvation Bio Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113226322-A | Heterocyclic compounds as BET inhibitors | 诺维逊生物股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-05-07 | — | — | US | disclosed |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | BET1, BRD4, BRD3 | PNMT 2273/4885ADRA2A 3312/4885ADRA2B 3012/4885 |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | PNMT 2085/4885ADRA2A 4314/4885ADRA2B 3761/4885 |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | BET1, BRD4, PHKB | PNMT 1009/4885ADRA2A 2649/4885ADRA2B 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.